Biogen’s Chief Executive Officer Michel Vounatsos is stepping down as it is grappling with Medicare restricting coverage for its Alzheimer’s drug Aduhelm.
Biogen’s Chief Executive Officer Michel Vounatsos is stepping down as it is grappling with Medicare restricting coverage for its Alzheimer’s drug Aduhelm.